dalteparin has been researched along with Fibrosis in 10 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Excerpt | Relevance | Reference |
---|---|---|
"The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 7.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
"The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 3.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 5 (50.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Gao, Z | 1 |
Li, S | 1 |
Zhao, J | 1 |
Li, J | 1 |
Gao, Y | 1 |
Spronk, HM | 1 |
De Jong, AM | 1 |
Verheule, S | 1 |
De Boer, HC | 1 |
Maass, AH | 1 |
Lau, DH | 1 |
Rienstra, M | 1 |
van Hunnik, A | 1 |
Kuiper, M | 1 |
Lumeij, S | 1 |
Zeemering, S | 1 |
Linz, D | 1 |
Kamphuisen, PW | 1 |
Ten Cate, H | 1 |
Crijns, HJ | 1 |
Van Gelder, IC | 1 |
van Zonneveld, AJ | 1 |
Schotten, U | 1 |
Diaz, JA | 1 |
Wrobleski, SK | 2 |
Alvarado, CM | 1 |
Hawley, AE | 2 |
Doornbos, NK | 1 |
Lester, PA | 1 |
Lowe, SE | 1 |
Gabriel, JE | 1 |
Roelofs, KJ | 1 |
Henke, PK | 3 |
Schaub, RG | 3 |
Wakefield, TW | 3 |
Myers, DD | 3 |
Ayata, M | 1 |
Kaptan, Z | 1 |
Uzunkulaoğlu, H | 1 |
Akyıldız, İ | 1 |
Tüzüner, A | 1 |
Ünverdi, H | 1 |
Karadaş, H | 1 |
Sood, V | 1 |
Luke, C | 1 |
Miller, E | 1 |
Mitsuya, M | 1 |
Upchurch, GR | 1 |
Emami, MJ | 1 |
Namazi, H | 1 |
Vosoughi, AR | 1 |
Nezhad, ST | 1 |
Oryan, A | 1 |
Mozaffarian, K | 1 |
Bedard, PW | 1 |
Kaila, N | 1 |
Shaw, G | 1 |
Meier, TR | 2 |
Assy, N | 1 |
Hussein, O | 1 |
Khalil, A | 1 |
Luder, A | 1 |
Szvalb, S | 1 |
Paizi, M | 1 |
Spira, G | 1 |
Baxi, S | 1 |
Crandall, DL | 1 |
Wrobleski, S | 1 |
Hawley, A | 1 |
Farris, D | 1 |
Elokdah, H | 1 |
Sigler, R | 1 |
Wakefield, T | 1 |
Myers, D | 1 |
Abe, W | 1 |
Ikejima, K | 1 |
Lang, T | 1 |
Okumura, K | 1 |
Enomoto, N | 1 |
Kitamura, T | 1 |
Takei, Y | 1 |
Sato, N | 1 |
1 trial available for dalteparin and Fibrosis
Article | Year |
---|---|
Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial.
Topics: Albumins; Anticoagulants; Esophageal and Gastric Varices; Fibrosis; Gastrointestinal Hemorrhage; Hum | 2023 |
9 other studies available for dalteparin and Fibrosis
Article | Year |
---|---|
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; F | 2017 |
P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor.
Topics: Animals; Aptamers, Nucleotide; Blood Coagulation; Collagen; Disease Models, Animal; Enoxaparin; Fibr | 2015 |
Effect of Enoxaparin Sodium on Experimentally-Induced Myringosclerosis in Rats.
Topics: Animals; Anticoagulants; Calcinosis; Disease Models, Animal; Enoxaparin; Fibrosis; Hyalin; Hyperemia | 2015 |
Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline.
Topics: Animals; Disease Models, Animal; Doxycycline; Elasticity; Enoxaparin; Fibrin Fibrinogen Degradation | 2010 |
Can enoxaparin prevent arthrofibrosis?
Topics: Animals; Enoxaparin; Fibrinolytic Agents; Fibrosis; Joint Diseases; Knee Joint; Male; Orthopedic Pro | 2012 |
Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis.
Topics: Animals; Anticoagulants; Constriction, Pathologic; Disease Models, Animal; Enoxaparin; Fibrosis; Hyd | 2006 |
The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis.
Topics: Animals; Aspartate Aminotransferases; Aspirin; Bilirubin; Disease Progression; Enoxaparin; Fibrinoly | 2007 |
Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxaparin; Fibrosis; Indoleaceti | 2008 |
Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat.
Topics: Actins; Animals; Carbon Tetrachloride; Collagen Type I; Collagen Type I, alpha 1 Chain; Dalteparin; | 2007 |